KRAS and neoplasm: The discrepancy between EBC and tumor as well as between blood and tumor was noted when KRAS mutation status (including the wild, not mutated sequence) detected in EBC and blood differed from mutation (or mutations) observed in corresponding set of five cancer tissue samples.